Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from imatinib to nilotinib versus continued imatinib in chronic-phase CML with MMR
2013-000077-68Phase 3Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Nilotinib switch with Imatinib continuation (2 arms). Primary endpoint: Proportion of patients with confirmed MR4 at two years of study treatment. Started Jun 2013; status: terminated.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-000077-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000077-68.